{
  "abstract": "BACKGROUND: The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1. METHODS: Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients (<65 years). Factors associated with olaparib efficacy, and safety in age subgroups, were also assessed. RESULTS: Of 806 randomised patients, 292 (36.2%) were ≥65 years. A lower proportion of older versus younger patients had an Eastern Cooperative Oncology Group performance status of 0 (61.0% versus 76.2%) and upfront surgery (42.0% versus 55.7%). Older patients were less likely to have a BRCA1/2 mutation (17.1% versus 36.7%) or homologous recombination deficiency-positive status (34.1% versus 55.7%). After median follow-up of 22.1 months, median PFS was 21.6 months with olaparib versus 16.6 months with placebo in the older population (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.41-0.75), comparable with the younger population (median 22.9 versus 16.9 months; HR 0.61, 95% CI 0.49-0.77). PFS benefits were observed in patients with a BRCA mutation or homologous recombination deficiency-positive tumours. Incidence of olaparib-related grade ≥3 adverse events in older patients was comparable with that of younger patients (36.8% versus 31.7%) although hypertension and anaemia were more common in older patients. No treatment-related deaths occurred in older patients receiving olaparib. CONCLUSION: Older patients enrolled in PAOLA-1 achieved similar PFS benefits compared with younger patients, with a similar safety profile.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 20,
  "authors": [
    {
      "name": "Renaud Sabatier"
    },
    {
      "name": "Frédérique Rousseau"
    },
    {
      "name": "Florence Joly"
    },
    {
      "name": "Claire Cropet"
    },
    {
      "name": "Coline Montégut"
    },
    {
      "name": "Johanna Frindte"
    },
    {
      "name": "Saverio Cinieri"
    },
    {
      "name": "Eva Guerra Alía"
    },
    {
      "name": "Stephan Polterauer"
    },
    {
      "name": "Hiroyuki Yoshida"
    },
    {
      "name": "Ignace Vergote"
    },
    {
      "name": "Nicoletta Colombo"
    },
    {
      "name": "Sakari Hietanen"
    },
    {
      "name": "Rémi Largillier"
    },
    {
      "name": "Ulrich Canzler"
    },
    {
      "name": "Alain Gratet"
    },
    {
      "name": "Frederik Marmé"
    },
    {
      "name": "Laure Favier"
    },
    {
      "name": "Eric Pujade-Lauraine"
    },
    {
      "name": "Isabelle Ray-Coquard"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/f5k606pj03mfs.bib",
  "cited_by": 20,
  "doi": "10.1016/j.ejca.2022.11.029",
  "fulltext_url": null,
  "id": "f5k606pj03mfs",
  "issns": [
    "0959-8049"
  ],
  "landing_url": "https://hal.science/hal-05744028v1",
  "language": "en",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "0.shs"
    ],
    [
      "openalex",
      "2730|PARP inhibition in cancer therapy"
    ]
  ],
  "openalex": "W4311424265",
  "pdf_url": "http://www.ejcancer.com/article/S0959804922017798/pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-09",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/f5k606pj03mfs.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:31Z",
      "native_id": "hal-05744028",
      "source": "hal",
      "url": "https://hal.science/hal-05744028v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|PARP inhibition in cancer therapy",
      "subfield": "oncology"
    }
  ],
  "title": "Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial",
  "title_text": "Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:31Z",
  "url": "https://research.draconitic.com/paper/f5k606pj03mfs",
  "venue": "European Journal of Cancer",
  "versions": []
}